- Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
- Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
- Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
- Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
- Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
- Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
- Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
- Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
- Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
- Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
More ▼
Key statistics
As of last trade, Lumos Pharma Inc (LUMO:NMQ) traded at 1.56, 13.86% above the 52 week low of 1.37 set on Jul 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.52 |
---|---|
High | 1.69 |
Low | 1.46 |
Bid | 1.47 |
Offer | 1.57 |
Previous close | 1.50 |
Average volume | 51.65k |
---|---|
Shares outstanding | 8.12m |
Free float | 5.29m |
P/E (TTM) | -- |
Market cap | 12.17m USD |
EPS (TTM) | -4.59 USD |
Data delayed at least 15 minutes, as of Jul 16 2024 17:06 BST.
More ▼